Aegis Life and Entos Reach Key Milestone in COVID Vaccine
Aegis Life and Entos Reach Key Milestone in COVID Vaccine
SAN DIEGO, Calif. & EDMONTON, Alberta--Aegis Life, Inc. (Aegis) and its partner Entos Pharmaceuticals (Entos) have announced that the Phase 1 portion of their clinical trial for Covigenix VAX-002, aimed at evaluating a COVID-19 booster vaccine, is fully enrolled. Covigenix VAX-002 is uniquely formulated using the Entos Fusogenix PLV technology, which employs plasmid DNA that expresses essential SARS-CoV-2 antigens. This innovative approach intends to protect against the latest circulating omicron strains of the virus.
Details About the Clinical Trial
The Phase 1/2 clinical trial for Covigenix VAX-002 is being conducted across 12 sites in Canada. The primary objective of the Phase 1 portion is to ascertain both the safety and the optimal dosing of the vaccine as a booster against COVID-19. The trial's design includes an interim analysis of the Phase 1 cohort, and findings from this analysis will guide the dosing schedule for the subsequent Phase 2 trial. The second phase aims to assess both the safety and immunogenicity response related to the optimal dose of the booster.
Dr. Steve Chen, the Chief Medical Officer at Aegis, expressed gratitude towards the participating sites and individuals. He emphasized the enthusiasm within the clinical community surrounding Covigenix VAX-002 and its potential to generate a robust immune response against the current SARS-CoV-2 strains. Chen remarked, "Our ability to enroll the Phase 1 portion of this study in just a few weeks showcases the excitement about Covigenix VAX-002, which we believe could provide a more durable and effective vaccine booster solution than those currently available."
Key Advantages of Fusogenix Technology
Recent studies validating the safety and efficacy of the Fusogenix technology have been published in esteemed journals. These studies highlight how the proteolipid vehicles, utilizing FAST proteins, can effectively address limitations associated with existing viral and non-viral genetic medicine delivery systems. The FAST-PLV system's advantages encompass improved delivery to specific tissues outside of the liver, the feasibility of re-dosing, and amplified expression of genetic medicines across a range of tissues.
About Aegis Life, Inc.
Aegis Life, Inc. is dedicated to developing next-generation genetic vaccines and therapies targeting some of the world’s most challenging infectious diseases. By harnessing the Fusogenix PLV platform initially developed by Entos Pharmaceuticals, Aegis Life can efficiently advance safe and effective RNA or DNA vaccines and therapeutics.
About Entos Pharmaceuticals Inc.
Entos Pharmaceuticals specializes in innovative genetic medicine solutions, focusing on the development of safe and effective nucleic acid delivery technologies. With a commitment to advancing next-generation genetic therapies utilizing the Fusogenix PLV drug delivery system, Entos is paving the way for life-changing medical treatments. The company has entered into collaborations with various global entities to expand and enhance the reach of its platform.
Frequently Asked Questions
What is Covigenix VAX-002?
Covigenix VAX-002 is a COVID-19 vaccine being developed as a booster using innovative DNA technology to provide protection against SARS-CoV-2.
What is the purpose of the ongoing clinical trial?
The trial aims to assess the safety and efficacy of Covigenix VAX-002, determining the optimal dosing needed for effective vaccination.
How is the Fusogenix technology advantageous?
The Fusogenix technology improves genetic material delivery to various tissues and allows for potential re-dosing, increasing the effectiveness of treatments.
Who is leading the development of Covigenix VAX-002?
Aegis Life, Inc. is spearheading the development, in collaboration with Entos Pharmaceuticals, which focuses on innovative drug delivery systems.
Where is the trial being conducted?
The Phase 1/2 clinical trial is being conducted at multiple sites across Canada.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.